Medline (NASDAQ:MDLN) Shares Break Below Two Hundred Day Moving Average - Here's Why

Medline logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Medline shares slipped below their 200-day moving average of $39.34, trading as low as $38.28 before last changing hands at $39.17.
  • Analyst sentiment remains positive overall: 23 analysts rate the stock a Buy, and the consensus is “Moderate Buy” with an average price target of $46.08.
  • Medline reported quarterly EPS of $0.44, beating the $0.32 consensus estimate, on revenue of $7.86 billion.
  • MarketBeat previews top five stocks to own in December.

Medline (NASDAQ:MDLN - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $39.34 and traded as low as $38.28. Medline shares last traded at $39.17, with a volume of 7,542,728 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. BMO Capital Markets restated an "outperform" rating and issued a $47.00 target price on shares of Medline in a research report on Thursday, August 6th. Leerink Partners lifted their price target on Medline from $43.00 to $46.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Deutsche Bank set a $37.00 price objective on shares of Medline and gave the stock a "hold" rating in a research note on Thursday, August 6th. Robert W. Baird set a $42.00 target price on shares of Medline in a research report on Thursday, August 6th. Finally, Bank of America lowered their price objective on Medline from $53.00 to $46.00 in a research report on Thursday, August 6th. Twenty-three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $46.08.

Get Our Latest Stock Analysis on MDLN

Medline Price Performance

The stock has a market capitalization of $51.52 billion and a price-to-earnings ratio of 89.02. The business's fifty day moving average price is $35.33 and its 200-day moving average price is $39.34. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51.

Medline (NASDAQ:MDLN - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The company had revenue of $7.86 billion for the quarter. On average, research analysts forecast that Medline will post 1.58 EPS for the current year.

Insider Transactions at Medline

In other news, major shareholder Private Ltd Gic sold 2,088,987 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the completion of the transaction, the insider directly owned 16,453,806 shares of the company's stock, valued at $576,705,900.30. This represents a 11.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 6,348,676 shares of company stock worth $224,525,137 in the last three months. Company insiders own 0.81% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDLN. Janus Henderson Group PLC lifted its position in Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company's stock valued at $506,546,000 after purchasing an additional 887,240 shares during the last quarter. Banque Pictet & Cie SA increased its holdings in Medline by 2.0% during the 3rd quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company's stock valued at $258,692,000 after purchasing an additional 142,939 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Medline by 233.3% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company's stock valued at $222,500,000 after buying an additional 3,500,000 shares during the period. Durable Capital Partners LP increased its position in shares of Medline by 80.2% during the third quarter. Durable Capital Partners LP now owns 4,734,627 shares of the company's stock valued at $164,292,000 after buying an additional 2,107,306 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Medline by 30,255.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company's stock worth $94,353,000 after acquiring an additional 2,691,529 shares in the last quarter.

Medline Company Profile

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medline Right Now?

Before you consider Medline, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medline wasn't on the list.

While Medline currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines